Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2025 03:00 ET | Source: Cyprumed GmbH

Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeuticsCyprumed will be eligible to receive up to $493 million in upfront, development, regulatory...
January 31, 2025 16:05 ET | Source: Evaxion Biotech

Evaxion announces closing of $10.8 million public offering

COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...
September 26, 2024 07:30 ET | Source: Evaxion Biotech

Evaxion significantly expands vaccine development collaboration with MSD

Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on...
May 29, 2024 02:00 ET | Source: Anaveon

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
April 05, 2023 07:00 ET | Source: Proxygen

Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders

VIENNA, Austria, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license...
March 16, 2021 08:00 ET | Source: Immutep Limited

Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer

New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...
March 05, 2021 08:00 ET | Source: Immutep Limited

Immutep Expands Part B of TACTI-002 Study

Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...
December 07, 2017 09:37 ET | Source: HealthEC

Medical Society of Delaware Partners with HealthEC To Provide Population Health Platform to Nearly 900 Physicians

NEWARK, Del. and PISCATAWAY, N.J., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Medical Network Management Services of Delaware, LLC (MedNet), a wholly-owned subsidiary of the Medical Society of Delaware...